This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kusama, M. Articles by Ferrone, S. Search for Related Content PubMed PubMed Citation Articles by Kusama, M. Articles by Ferrone, S.

Syngeneic Antiidiotypic Antisera to Murine Antihuman High-Molecular-Weight Melanoma-associated Antigen Monoclonal Antibodies¹

Department of Microbiology and Immunology, New York Medical College, Valhalla, New York 10595

BALB/c mice were immunized with the murine antihuman high-molecular-weight melanoma-associated antigen monoclonal antibodies (MoAbs) 149.53, 225.28, 653.25, and 763.74. Antidiotypic antibodies could be detected in bleedings obtained 3 days following the first booster, increased in titer in bleedings obtained following the second booster, and persisted at high level in bleedings obtained 38 days following the second booster. Cross-blocking studies with a panel of anti-melanoma-associated antigen, anti-HLA Class I, and anti-HLA Class II monoclonal antibodies showed that the antisera recognize private idiotypes. The latter are located within the antigen combining site, since antiidiotypic antisera specifically inhibited the binding of the corresponding immunizing antihuman high-molecular-weight melanoma-associated antigen monoclonal antibody to cultured human melanoma cells Colo 38 in a dose-dependent fashion. The spectrotype of the anti-MoAb 149.53 antiserum comprises eight major components in the range of pH 6.2 to 7.0; those of the anti-MoAb 225.28 antiserum and of the anti-MoAb 653.25 antiserum, two major components in the ranges of pH 6.4 to 6.6 and 6.5 to 6.7, respectively; and that of the anti-MoAb 763.74 antiserum, three major components in the range of pH 6.2 to 6.4.

¹ This work was supported by NIH Grants AI21384, CA37959, and CA38469. Portions of this work were presented previously (42).

² Supported by a research fellowship from the Associazione Italiana per la Ricerca sul Cancro.

³ To whom requests for reprints should be addressed.

Received 9/15/86. Revised 2/18/87. Accepted 5/21/87.